BRIEF-Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints

Zenas BioPharma

ZBIO

0.00

June 2 (Reuters) - Zenas Biopharma Inc ZBIO.O:

ZENAS BIOPHARMA ANNOUNCES DATA FROM THE REGISTRATIONAL PHASE 3 INDIGO TRIAL OF OBEXELIMAB IN IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD), SIMULTANEOUSLY PRESENTED AT THE EULAR 2026 CONGRESS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
ZENAS BIOPHARMA - PHASE 3 INDIGO TRIAL OF OBEXELIMAB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS
ZENAS BIOPHARMA - OBEXELIMAB SIGNIFICANTLY LOWERS GLUCOCORTICOID USE AND TOXICITIES IN INDIGO TRIAL

Source text: ID:nGNX571Qg7

Further company coverage: ZBIO.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.